Today: 21 May 2026
Browse Category

NASDAQ:GRRR 18 November 2025 - 7 December 2025

Gorilla Technology (GRRR) Stock on December 7, 2025: Latest News, CVR Shake-Up, Forecasts and Analyst Outlook

Gorilla Technology (GRRR) Stock on December 7, 2025: Latest News, CVR Shake-Up, Forecasts and Analyst Outlook

Gorilla Technology (NASDAQ: GRRR) closed at $14.97 on December 5, down 3.36%, with after-hours trading at $15.03 and a market cap near $430 million. Q3 revenue reached a record $26.5 million, up 32% year-on-year. The company reported a $1.4 billion AI data-center mandate and a $7 billion pipeline. Analyst price targets vary widely, from $18 to $39.
7 December 2025
·
Gorilla Technology Group (GRRR) Stock: CVR Payout, Nobel Sustainability Nomination and a $1.4 Billion AI Bet – What Investors Need to Know Now

Gorilla Technology Group (GRRR) Stock: CVR Payout, Nobel Sustainability Nomination and a $1.4 Billion AI Bet – What Investors Need to Know Now

Gorilla Technology (NASDAQ: GRRR) closed at $14.97 on Dec. 5, 2025, with a market cap near $350–430 million and short interest at 12%. The company secured a $1.4 billion AI data-center contract in Southeast Asia and reported record revenue, but posted a $67 million net loss over the past year. GRRR shares are up over 150% in 12 months but down 20–25% in the past six months. Analyst opinions remain sharply split.
6 December 2025
·
Gorilla Technology (GRRR) Soars on Record Q3 Earnings, $1.4B AI Data Centre Deal and Bullish 2026 Outlook

Gorilla Technology (GRRR) Soars on Record Q3 Earnings, $1.4B AI Data Centre Deal and Bullish 2026 Outlook

Gorilla Technology Group shares surged November 18 after the company reported record Q3 2025 results, including $26.5 million in revenue, a swing to positive operating income, and near-breakeven net loss. The company confirmed a $1.4 billion AI data centre mandate in Southeast Asia and reported cash of $121.4 million with debt down to $15.1 million.
18 November 2025
····

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop